EUVIMEDEUVIMED entdecken
Open Access · CC0

Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States

Carla V Rodriguez-Watson, Natalie E Sheils iD, Anthony M Louder, Elizabeth H Eldridge, Nancy D Lin, Benjamin D Pollock, Jennifer L Gatz, Shaun J Grannis, Rohit Vashisht, Kanwal Ghauri, Gina Valo, Aloka G Chakravarty iD und 20 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0281365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Carla V Rodriguez-Watson und 31 weiteren Autor:innen. Beteiligte Einrichtung: Reagan-Udall Foundation for the FDA, Washington, District of Columbia, United States of America. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: FDA HHS, Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation, U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As diagnostic tests for COVID-19 were broadly deployed under Emergency Use Authorization, there emerged a need to understand the real-world utilization and performance of serological testing across the United States.

Methods

Six health systems contributed electronic health records and/or claims data, jointly developed a master protocol, and used it to execute the analysis in parallel. We used descriptive statistics to examine demographic, clinical, and geographic characteristics of serology testing among patients with RNA positive for SARS-CoV-2.

Results

Across datasets, we observed 930,669 individuals with positive RNA for SARS-CoV-2. Of these, 35,806 (4%) were serotested within 90 days; 15% of which occurred 30%) in some datasets—limiting our ability to examine differences in serological testing by race. In datasets where race/ethnicity information was available, we observed a greater distribution of White individuals among those serotested; however, the time between RNA and serology tests appeared shorter in Black compared to White individuals. Test manufacturer data was available in half of the datasets contributing to the analysis.

Conclusion

Our results inform the underlying context of serotesting during the first year of the COVID-19 pandemic and differences observed between claims and EHR data sources–a critical first step to understanding the real-world accuracy of serological tests. Incomplete reporting of race/ethnicity data and a limited ability to link test manufacturer data, lab results, and clinical data challenge the ability to assess the real-world performance of SARS-CoV-2 tests in different contexts and the overall U.S. response to current and future disease pandemics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansUnited StatesRNAPandemicsCOVID-19 Testing

Substanzen

RNA

Autor:innen und Institutionen

  • Reagan-Udall Foundation for the FDA, Washington, District of Columbia, United States of America.
  • OptumLabs, Minnetonka, Minnesota, United States of America.
  • Aetion, New York, New York, United States of America.
  • Health Catalyst, Salt Lake City, Utah, United States of America.
  • Mayo Clinic, Rochester, Minnesota, United States of America.
  • Regenstrief Institute, Indianapolis, Indiana, United States of America.

ORCID-Profile: Natalie E Sheils, Aloka G Chakravarty, Jacqueline M Major, Sandy Leonard, Carrie L Byington, Jeff Allen

Förderung

  • FDA HHS
  • Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation
  • U.S. Food and Drug Administration
  • Rockefeller Foundation

Zitieren

APA

Rodriguez-Watson, C. V., Sheils, N. E., Louder, A. M., Eldridge, E. H., Lin, N. D., Pollock, B. D., Gatz, J. L., Grannis, S. J., Vashisht, R., Ghauri, K., Valo, G., Chakravarty, A. G., Lasky, T., Jung, M., Lovell, S. L., Major, J. M., Kabelac, C., Knepper, C., Leonard, S., …, & Allen, J. (2023). Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States. PLOS ONE. https://doi.org/10.1371/journal.pone.0281365

Vancouver

Rodriguez-Watson CV, Sheils NE, Louder AM, Eldridge EH, Lin ND, Pollock BD, et al. Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States. PLOS ONE. 2023. doi:10.1371/journal.pone.0281365

BibTeX
@article{RodriguezWatson2023,
  author = {Rodriguez-Watson, Carla V and Sheils, Natalie E and Louder, Anthony M and Eldridge, Elizabeth H and Lin, Nancy D and Pollock, Benjamin D and Gatz, Jennifer L and Grannis, Shaun J and Vashisht, Rohit and Ghauri, Kanwal and Valo, Gina and Chakravarty, Aloka G and Lasky, Tamar and Jung, Mary and Lovell, Stephen L and Major, Jacqueline M and Kabelac, Carly and Knepper, Camille and Leonard, Sandy and Embi, Peter J and Jenkinson, William G and Klesh, Reyna and Garner, Omai B and Patel, Ayan and Dahm, Lisa and Barin, Aiden and Cooper, Dan M and Andriola, Tom and Byington, Carrie L and Crews, Bridgit O and Butte, Atul J and Allen, Jeff},
  title = {Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0281365}
}
Kostenlos starten →